Select region:

Clinical trials located in

Brest

Brest city is located in France. Currently, 20 clinical trials are being conducted in this city.

Brest, located in Brittany, France, is a city with a rich maritime history. Established by the Romans, it has evolved into a significant naval port. The city was almost entirely rebuilt after World War II, due to extensive bombing. Brest is home to the National Maritime Museum, showcasing its naval heritage. The Océanopolis aquarium is another highlight, offering a deep dive into marine ecosystems. The Recouvrance Bridge, a vertical-lift bridge, and the Tanguy Tower, housing a museum on the history of Brest, are notable landmarks.

  • CT-EU-00083874

    Study to find the best way to administer pegaspargase in children with acute lymphoblastic leukemia

    This is a study to investigate treatment strategies for children and adolescents diagnosed with acute lymphoblastic leukemia (ALL). The study focuses on evaluating the efficacy of a drug called pegaspargase. The drug works by depriving tumor cells of essential nutrients, contributing to its potential efficacy against ALL in pediatric patients. The study aims to determine the optimal way to administer pegaspargase, comparing a single high dose with two lower doses, with additional doses later in treatment. For those at highest risk, a more intensive treatment plan is being investigated. This includes two larger initial doses, followed by additional doses later in treatment. The study is evaluating factors such as potential serious side effects and overall treatment efficacy.

  • Continued Parsaclisib treatment for B-cell cancer patients

    This is a phase II clinical trial focused on providing continuation of treatment with a drug called parsaclisib to people diagnosed with B-cell malignancies. The main goal of this study is to expand the treatment regimen established in the previous study. Study participants will receive parsaclisib as a stand-alone therapy (monotherapy) or in combination with other therapeutic agents, which may include itacitinib, ruxolitinib or ibrutinib. The study aims to facilitate participants’ ongoing care and contribute to the broader field of medical research by collecting data on the effectiveness and safety of prolonged use of parsaclisib.

    AustriaBelgiumCzechiaDenmarkFranceHungaryItalyNorwayPolandSpainSwedenUnited Kingdom
  • Examining capivasertib and docetaxel in advanced prostate cancer

    This trial is testing a new potential treatment for a type of advanced prostate cancer. The study will compare two combinations: one with Capivasertib and another called Docetaxel, compared with placebo (a dummy tablet with no medical effect) and Docetaxel. In addition, each study participant will receive steroid treatment and another therapy called androgen deprivation therapy. The main goal of this study is to demonstrate whether Capivasertib + Docetaxel extends patients’ lives more than placebo + Docetaxel. They will also be monitored for the time it takes for the cancer to show signs of growth again, for the pain to increase or for urinary symptoms to worsen.

    BelgiumCzechiaFranceGreeceHungaryNetherlandsPolandSpainUnited Kingdom
  • Stomach cancer treatment comparison: trastuzumab deruxtecan vs. ramucirumab & paclitaxel

    This is a thorough comparison study to measure the effectiveness and safety of two treatment paths. It’s designed for individuals who have experienced progression regarding a stomach (gastric) cancer, or cancer of the gastro-esophageal junction (GEJ). The study focuses on those with HER2-positive gastric or GEJ who have previously undergone a trastuzumab-containing regime but have not received further systemic therapy.The research compares the use of trastuzumab deruxtecan, a potent anti-cancer agent, and the combined use of ramucirumab and paclitaxel. The study’s primary goal is to evaluate the overall survival rate, while secondary aims involve examining progression-free survival, response duration, disease control, safety, pharmacokinetics, and immunogenicity.In the study, participants are fairly and randomly assigned to receive one of two treatments. This is crucial in understanding the superiority and safety of these treatment paths, and this knowledge may inform future approaches to treating these types of cancer.

    BelgiumFranceHungaryItalyPolandPortugalRomaniaSpainUnited Kingdom
  • Testing a new combination therapy with acalabrutinib for a specific type of lymphoma

    This clinical trial is investigating a new combination therapy for diffuse large B-cell lymphoma, a type of lymphoma. The treatment combines Acalabrutinib, a targeted therapy drug, with R-CHOP, a chemotherapy mix consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, a standard chemotherapy regimen. The aim of the study is to evaluate the safety and effectiveness of this combination in improving patient outcomes. It focuses on patients who have not been previously treated for lymphoma. The study aims to find better treatment strategies for this particular type of lymphoma.

    AustriaBelgiumCzechiaFranceGermanyItalyPolandPortugalSpain
  • Evaluating ways to reduce Amivantamab infusion reactions

    This trial is designed to test how well three different medications, Dexamethasone, Montelukast, and Methotrexate, can limit the unpleasant reactions that might occur when a patient is given the drug Amivantamab by intravenous infusion with oral Lazertinib (combination therapy used to treat non-small cell lung cancer). These three drugs are given before the infusion of Amivantamab. The study will also record how long the entire infusion procedure lasts, including the administration of the pre and post infusion medications, and the percentage of people who complete the procedure within 4 hours.

    FranceSpain
  • Testing a new inhaled drug for pulmonary arterial hypertension

    This study focuses on the efficiency and safety of a new inhaled drug – MK-5475 – for patients suffering from Pulmonary Arterial Hypertension (PAH). The study is divided into two parts: phase 2 and phase 3. In phase 2, the researchers will compare three different doses of MK-5475 with a placebo over a base period of 12 weeks. The goal is to find out if any of the doses can decrease the patient’s pulmonary vascular resistance (PVR), which is the resistance that the heart must overcome to pump blood through the lungs. In Phase 3 of the study, the best performing dose from Phase 2 will be used to confirm its long-term effectiveness, safety, and tolerability over a 12-week base period with a follow-up period of up to five years. The focus is to see if this dose is better than a placebo in improving the patient’s walking distance over 6 minutes. The study aims at improving the quality of life and physical health of PAH patients with the help of the new drug.

    BelgiumFranceGermanyItalyPolandSwedenUnited Kingdom
  • Study of trastuzumab deruxtecan in gastric cancer or gastroesophageal junction adenocarcinoma

    The aim of the DESTINY-Gastric04 study is to help cancer patients suffering from certain diseases. These patients have a specific type of stomach cancer or adenocarcinoma of the gastroesophageal junction that has not responded to treatment or has gotten worse after treatment with a medicine called trastuzumab. This study is testing a new drug called trastuzumab deruxtecan, comparing it with a combination of two other drugs – ramucirumab and paclitaxel. A key goal of this study is to determine how long participants will live after starting a new treatment. It will also be observed whether the cancer will shrink or stop growing, how long it will last, what the potential side effects of treatment will be and how the body will respond to the new drug.

    BelgiumFranceHungaryItalyPolandPortugalRomaniaSpainUnited Kingdom
  • Sotatercept treatment study for new Pulmonary Hypertension patients

    This study is an important test where doctors are looking at how a drug called Sotatercept can help people struggling with Pulmonary Arterial Hypertension (or PAH for short). The goal is to see whether this drug can delay or prevent the condition from getting worse. PAH makes it really hard for patients to breathe because it affects lungs and heart. The testing process is being done in a fair and careful way. Half of the patients will get the drug, and the others will get a ‘placebo’ which doesnt contain any medicine. The doctors will look at the effect on patients over time. The study is looking specifically at patients who were recently diagnosed with PAH and are at risk for the disease to get worse.

    AustriaBelgiumCzechiaDenmarkFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom
  • Testing new potential drug for blood cancer treatment

    This study investigates the potential treatment BMS-986158 for Myelofibrosis, a type of blood cancer. The research is designed to assess the safety and effectiveness of BMS-986158, both as a standalone treatment and in combination with other drugs like Ruxolitinib or Fedratinib. The study is divided into two main parts: the first part examines the combination of BMS-986158 with either Ruxolitinib or Fedratinib, while the second part evaluates the BMS-986158 in combination with either Ruxolitinib or Fedratinib and BMS-986158 alone. The primary objectives include ensuring the safety of the treatment and observing its ability to prevent the progression of cancer and spleen-related issues.

    FranceGermanyGreeceItalyPolandRomaniaSpain
  • Understanding the effectiveness and safety of different treatments for advanced upper gastrointestinal tract cancer

    This is a study about a treatment method for adults with advanced upper gastrointestinal tract cancer. The treatment method could combine different therapies, some with standard cancer drugs and others without. The aim of this study is to see if the new combinations are safe and help control the cancer. The medicines in the chemotherapy mixture are known as FOLFOX, which includes Oxaliplatin, Leucovorin, and Fluorouracil. Participants divided into groups will receive combinations of drugs such as Domvanalimab, Quemliclustat, Zimberelimab with or without FOLFLOX.

    France
  • Study of combination therapy for Prostate Cancer treatment

    This study focuses on testing a new treatment approach for medium-high risk prostate cancer. The therapy, called darolutamide, will be administered with radiation therapy to evaluate its efficacy in destroying cancer cells more effectively. The trial is divided into two ‘arms’: one arm involves patients receiving darolutamide alongside radiation therapy for six months, while the other arm involves patients receiving a different form of therapy (androgen deprivation therapy) along with the same radiation therapy. By comparing the effects of these two treatments, doctors aim to determine which one is more effective against prostate cancer. PSA levels are also used by researchers to assess treatment response in patients.

    France
  • Testing the safety and effectiveness of alpelisib for MCAP syndrome

    This study is testing a medication called Alpelisib in people with a rare condition called Megalencephaly-Capillary Malformation Polymicrogyria Syndrome (MCAP). The study will be split into two sections. The first is a 6-month trial where some people will be given Alpelisib and others a placebo (a harmless, inactive substance), but no one will know which group they are in. This is to precisely measure the medication’s effects. After this, all qualifying participants will receive Alpelisib for the remaining 18 months. Participants’ progress will be monitored regularly, and the effects of the medicine will be assessed primarily using a scale that measures improvement in everyday skills and quality of life. The study also examines the medicine’s impact on brain growth and function using MRI scans and other tests.

    France
  • Different treatment combinations for advanced pancreatic cancer study

    This trial is about trying out different ways to control late-stage pancreatic cancer. The current standard treatment for patients with this type of cancer is a mix of drugs called FOLFIRINOX (Leucovorin (Folinic Acid), Fluorouracil, Irinotecan). However, doctors are not sure when they should stop or reduce this treatment after the cancer has been controlled for a while. So, in this study, they want to see if a new drug called OSE2101 can help keep the cancer from getting worse. Patients will either get OSE2101 with FOLFIRI (a kind of maintenance therapy), or FOLFIRI alone after the FOLFIRINOX treatment is stopped. The study also aims to assess the safety of OSE2101 in patients with advanced pancreatic cancer.

    France
  • Studying repotrectinib effect on advanced solid tumors

    In this trial, the researchers are working on a new medicine called Repotrectinib, targeting people with specific types of advanced solid tumors. This medicine might be most helpful if cancer has certain genetic changes, specifically those called ALK, ROS1, or NTRK1-3. It is an early stage of testing Repotrectinib in two parts or phases. During Phase 1,the researchers are trying to find out what the right dose is. It is important to look at the highest dose that can be given without causing too many side effects, and also the dose makes a difference in how the cancer behaves. This phase will also look at how the medication is processed by the body and how it behaves in the system. The second phase will check how well the medicine works in different groups of people, with some details about their cancer and the treatments they have had in the past. It is important to check if the medicine can shrink the tumors and stop them from growing. The researchers will also measure how long these effects last, how quickly these effects occur.

    BelgiumDenmarkFranceGermanyHungaryItalyNetherlandsPolandSpainUnited Kingdom
  • Testing ADT with or without darolutamide in prostate cancer patients

    This study is about testing how well two different kinds of prostate cancer treatment work. One treatment is called ADT (Androgen deprivation therapy) and the other is called darolutamide. In total, around 300 men who have just been diagnosed with prostate cancer will take part. The people in the study will be split into two groups. Half of the people will have the ADT treatment with placebo, while the other half will have both the ADT and darolutamide treatment. This will help the researchers understand whether adding darolutamide makes the ADT treatment work better. To check how well the treatment is working, the researchers will be using different methods.

    BelgiumFranceSpain
  • Testing mavacamten for heart muscle disease

    This study aims to assess a drug called Mavacamten for a heart condition called Non-Obstructive Hypertrophic Cardiomyopathy. Patients will be randomly given either the actual drug or a placebo without anyone knowing which one they’ve received. The study will measure how safe and effective the drug is for patients with symptoms of this heart condition. The success of the drug will be determined by preventing heart-related issues such as heart attacks, strokes, heart failures, irregular heartbeats, and the need for a heart-rhythm controlling device.

    AustriaBelgiumCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsNorwayPolandPortugalSpainUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Study of secukinumab treatment for Giant Cell Arteritis

    This study is testing a drug called Secukinumab to see if it is safe and effective in people with a disease known as giant cell arteritis (GCA). GCA affects blood vessels in the body, causing inflammation. In this study, patients will receive Secukinumab or placebo (a treatment without active medicine) along with a medicine called glucocorticoids, the dose of which will be gradually reduced. The test will test whether a 26-week treatment course is more effective than the current 52-week treatment course. The research team will monitor whether the inflammation subsides and does not return throughout the year. The team will also check how long it will take until the disease symptoms return, how many glucocorticosteroids the patient will need within a year and how his quality of life has improved.

    AustriaBelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNorwayPolandPortugalSpainSwedenUnited Kingdom

See more clinical trials in other cities in France:

.